SCHEDULE: Qiming Funds Disclose 5.97% Stake in Zai Lab

Qiming Corporate GP IV, Ltd. and affiliated entities reported a 5.97% beneficial ownership stake in Zai Lab Limited as of June 30, 2025.

Summary

• Qiming Corporate GP IV, Ltd., along with Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P., Qiming Venture Partners IV, L.P., and QM11 Limited, collectively reported beneficial ownership of 66,329,320 Ordinary Shares of Zai Lab Limited.
• This aggregate amount represents 5.97% of Zai Lab Limited's Ordinary Shares outstanding.
• The percentage is calculated based on 1,110,783,740 Ordinary Shares outstanding as of June 30, 2025, as disclosed by Zai Lab Limited on July 7, 2025.
• QM11 Limited is the direct owner of the 66,329,320 Ordinary Shares, which are stated to consist of 1,268,000 American Depositary Shares (ADSs) and 53,649,320 ordinary shares.
• Qiming Corporate GP IV, Ltd. holds sole voting and dispositive power over the entire 66,329,320 shares.
• Qiming Managing Directors Fund IV, L.P. holds shared voting and dispositive power over 2,030,208 shares, representing 0.18% of the class.
• Qiming GP IV, L.P. and Qiming Venture Partners IV, L.P. each hold shared voting and dispositive power over 64,299,112 shares, representing 5.79% of the class.

Sentiment

Score: 6

Explanation: The filing is a routine beneficial ownership disclosure, indicating a significant and continued stake by a major venture capital firm in Zai Lab Limited, which can be viewed as a neutral to slightly positive signal of institutional confidence.

Positives

• The continued disclosure of a significant beneficial ownership stake (5.97%) by a prominent venture capital group like Qiming indicates ongoing institutional confidence in Zai Lab Limited.

Risks

• No specific operational or financial risks for Zai Lab Limited were disclosed in this beneficial ownership filing, as its primary purpose is to report shareholdings.

Future Outlook

This filing is a beneficial ownership report and does not contain any forward-looking statements or guidance from Zai Lab Limited or the reporting entities regarding the company's future performance or strategy.

Industry Context

Zai Lab Limited operates in the biotechnology and pharmaceutical industry, focusing on developing and commercializing innovative medicines. Qiming Venture Partners is a leading venture capital firm with significant investments in healthcare and technology. This filing indicates continued investment by a major VC firm in the biotech sector, aligning with broader trends of institutional interest in innovative healthcare companies.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's continued stake, which may provide a degree of stability or confidence regarding the company's long-term prospects.

Key Dates

Recommendation

This filing is a beneficial ownership report and does not contain operational or financial performance data for Zai Lab Limited. However, the disclosure of a significant 5.97% stake by Qiming Corporate GP IV, Ltd. and its affiliates, a prominent venture capital firm, suggests continued institutional confidence in the company. Investors should hold their positions while awaiting further operational updates and financial results.

Keywords

Zai Lab, Qiming, beneficial ownership, Schedule 13G, institutional investor, biotech, pharmaceuticals, China, equity stake